Nothing Special   »   [go: up one dir, main page]

MX347734B - Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. - Google Patents

Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.

Info

Publication number
MX347734B
MX347734B MX2012014678A MX2012014678A MX347734B MX 347734 B MX347734 B MX 347734B MX 2012014678 A MX2012014678 A MX 2012014678A MX 2012014678 A MX2012014678 A MX 2012014678A MX 347734 B MX347734 B MX 347734B
Authority
MX
Mexico
Prior art keywords
antibodies
therapeutic uses
therapeutic
preparation
methods
Prior art date
Application number
MX2012014678A
Other languages
English (en)
Other versions
MX2012014678A (es
Inventor
Tatiana Roque Navarro Lourdes
Luis Hernández Míguez José
Adan Plana Jaume
Maria Martínez Escolà Josep
Masa Álvarez Marc
Messeguer Peypoch Ramon
Mitjans Prat Francesc
Dakhel Plaza Sheila
Coll Manzano Antonio
Mª HERVAS VILLEGAS ROSA
Calvis Calpe Carmen
Padilla García Laura
Barberà Ferrando Laura
Rivas Cañas Manuel
Angel Gomez Casajus Luis
Original Assignee
Lykera Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43617041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347734(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lykera Biomed Sa filed Critical Lykera Biomed Sa
Publication of MX2012014678A publication Critical patent/MX2012014678A/es
Publication of MX347734B publication Critical patent/MX347734B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a anticuerpos contra S100A4, métodos para la preparación de estos anticuerpos, composiciones farmacéuticas que comprenden estos anticuerpos, y usos terapéuticos y de diagnóstico de los mismos.
MX2012014678A 2010-06-14 2011-06-14 Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. MX347734B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382170 2010-06-14
PCT/EP2011/059868 WO2011157724A1 (en) 2010-06-14 2011-06-14 S100a4 antibodies and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
MX2012014678A MX2012014678A (es) 2013-02-26
MX347734B true MX347734B (es) 2017-05-11

Family

ID=43617041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014678A MX347734B (es) 2010-06-14 2011-06-14 Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.

Country Status (21)

Country Link
US (2) US8916152B2 (es)
EP (1) EP2580240B1 (es)
JP (2) JP6081911B2 (es)
KR (1) KR101869413B1 (es)
CN (1) CN103201290B (es)
AU (3) AU2011267089B2 (es)
BR (1) BR112012032008B1 (es)
CA (1) CA2802631C (es)
CL (1) CL2012003538A1 (es)
CY (1) CY1121742T1 (es)
DK (1) DK2580240T3 (es)
ES (1) ES2717908T3 (es)
IL (1) IL223667B (es)
LT (1) LT2580240T (es)
MX (1) MX347734B (es)
NZ (1) NZ604643A (es)
PL (1) PL2580240T3 (es)
PT (1) PT2580240T (es)
RU (1) RU2615684C2 (es)
TR (1) TR201903026T4 (es)
WO (1) WO2011157724A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2717908T3 (es) * 2010-06-14 2019-06-26 Lykera Biomed S A Anticuerpos S100A4 y usos terapéuticos de los mismos
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
RU2484096C1 (ru) * 2012-02-08 2013-06-10 Общество с ограниченной ответственностью "Технофарма" ОДНОДОМЕННОЕ АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ БЕЛОК S100A4/Mts1, ПРИМЕНЕНИЕ ПОЛУЧЕННОГО АНТИТЕЛА ДЛЯ ДЕТЕКЦИИ ЭТОГО БЕЛКА
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
WO2014073653A1 (ja) * 2012-11-09 2014-05-15 国立大学法人福井大学 腎炎の病変部位の検査方法およびそのための試薬
JP2014094919A (ja) * 2012-11-09 2014-05-22 Univ Of Fukui 腎炎の予防または治療剤
US9914768B2 (en) 2013-04-09 2018-03-13 Lykera Biomed, S.A. Anti-S100A7 antibodies for the treatment and diagnosis of cancer
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
CN112083167B (zh) * 2019-06-14 2024-03-26 复旦大学附属华山医院 S100a4作为评估甲氨蝶呤干预银屑病的生物标记物及其用途
KR102151133B1 (ko) * 2019-12-27 2020-09-02 주식회사 인투앱 프로피오니박테리움 아크네스에 특이적으로 결합하는 신규한 항체 및 이의 용도
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US20230220058A1 (en) 2020-06-30 2023-07-13 Arxx Therapeutics As Anti-S100A4 antibodies for the treatment of systemic sclerosis
CN117480182A (zh) * 2021-02-09 2024-01-30 艾瑞克斯疗法有限公司 抗s100a4人源化抗体、用途和方法
CN113718029A (zh) * 2021-10-22 2021-11-30 中国人民解放军北部战区总医院 S100a4蛋白在动脉粥样硬化性肾动脉狭窄诊断中的应用
WO2023089131A1 (en) * 2021-11-19 2023-05-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN117686722B (zh) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US6638504B1 (en) * 1990-07-09 2003-10-28 Research Corporation Technologies, Inc. Methods for treating cancer
ATE152629T1 (de) 1990-07-09 1997-05-15 Res Corp Technologies Inc Diagnose von krebs-metastasen durch das mts-1 gen
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
JP2002542297A (ja) * 1999-04-23 2002-12-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 血管形成を増強するための治療組成物および方法
NL1013865C2 (nl) 1999-12-16 2001-06-21 Haarman Innovation Man Bvba Werkwijze voor het bepalen van ten minste ÚÚn materiaal in een object, en apparaten voor de uitvoering daarvan.
DE10017249A1 (de) 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
BR0207310A (pt) 2001-12-18 2004-08-17 Mondobiotech Sa Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
EP1466016A2 (en) 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Cancer profiles
US20040157278A1 (en) 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
US20040229225A1 (en) 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
US20050208518A1 (en) 2003-05-16 2005-09-22 Longueville Francoise D Method and apparatus for determination of RNAi cell transfection effects by multiple gene expression analysis on micro-arrays
DE602004018776D1 (de) 2003-07-04 2009-02-12 Johnson & Johnson Res Pty Ltd Verfahren zum nachweis von alkyliertem cytosin in dna
US20050118613A1 (en) 2003-08-01 2005-06-02 Oncomethylome Sciences S.A. Methods and kits for predicting the likelihood of successful treatment of cancer
US20080039413A1 (en) 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2006052795A2 (en) 2004-11-05 2006-05-18 University Of Rochester Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
KR100664589B1 (ko) 2004-12-28 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 및이를 포함하는 발현 벡터
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20060269948A1 (en) 2005-05-16 2006-11-30 Halloran Philip F Tissue rejection
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2121740A2 (en) * 2005-12-20 2009-11-25 Copenhagen University Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
TW200745556A (en) 2006-01-24 2007-12-16 Ind Tech Res Inst Biomarkers for liver fibrotic injury
JP2007263896A (ja) 2006-03-29 2007-10-11 Univ Nagoya 肺癌患者の術後予後予測のための生物マーカー及びその方法
WO2007126391A1 (en) 2006-04-28 2007-11-08 Singapore Health Services Pte Ltd Investigation of mucosa dryness conditions
WO2008030278A2 (en) 2006-06-05 2008-03-13 Fred Hutchinson Cancer Research Center Assays for radiation exposure
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008037432A2 (en) 2006-09-27 2008-04-03 Charité - Universitätsmedizin Berlin METHODS FOR DIAGNOSING METASTASIS BY ANALYZING MUTATIONS IN β-CATENIN
US20100248225A1 (en) 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
CA2669600A1 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of lung cancer
DE102006056784A1 (de) 2006-12-01 2008-06-05 Meyer, Helmut E., Prof.Dr. Biomarker für die Diagnose von Pankreaskrebs
US20080234138A1 (en) 2006-12-08 2008-09-25 Shaughnessy John D TP53 gene expression and uses thereof
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US20080161203A1 (en) 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
US20100120788A1 (en) 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
CA2680692A1 (en) 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
CA2682827A1 (en) 2007-04-05 2008-10-16 Source Precision Medicine, Inc., D/B/A Source Mdx Gene expression profiling for identification, monitoring and treatment of ovarian cancer
EP2145024A2 (en) 2007-04-06 2010-01-20 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of cervical cancer
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US20090093005A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
ES2717908T3 (es) * 2010-06-14 2019-06-26 Lykera Biomed S A Anticuerpos S100A4 y usos terapéuticos de los mismos

Also Published As

Publication number Publication date
WO2011157724A1 (en) 2011-12-22
JP2013531655A (ja) 2013-08-08
KR20130137583A (ko) 2013-12-17
RU2013101529A (ru) 2014-07-20
JP6081911B2 (ja) 2017-02-15
KR101869413B1 (ko) 2018-06-20
CN103201290A (zh) 2013-07-10
JP6564408B2 (ja) 2019-08-21
EP2580240B1 (en) 2018-11-28
CA2802631A1 (en) 2011-12-22
AU2017200281B2 (en) 2018-12-06
CY1121742T1 (el) 2020-07-31
CN103201290B (zh) 2016-09-28
AU2011267089B2 (en) 2017-02-16
ES2717908T3 (es) 2019-06-26
NZ604643A (en) 2015-04-24
US9657092B2 (en) 2017-05-23
DK2580240T3 (en) 2019-03-25
AU2017200281A1 (en) 2017-02-02
CA2802631C (en) 2019-12-17
PL2580240T4 (pl) 2020-03-31
MX2012014678A (es) 2013-02-26
AU2011267089A1 (en) 2013-01-17
PL2580240T3 (pl) 2020-03-31
PT2580240T (pt) 2019-03-29
EP2580240A1 (en) 2013-04-17
TR201903026T4 (tr) 2019-04-22
US20130101592A1 (en) 2013-04-25
US8916152B2 (en) 2014-12-23
BR112012032008A2 (pt) 2016-10-04
LT2580240T (lt) 2019-06-10
BR112012032008B1 (pt) 2020-05-26
AU2018264107A1 (en) 2018-12-06
IL223667B (en) 2018-03-29
US20150079097A1 (en) 2015-03-19
RU2615684C2 (ru) 2017-04-06
CL2012003538A1 (es) 2014-02-14
JP2017101050A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2020012426A (es) Anticuerpos anti-cd38.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
EA201370018A1 (ru) Составы рифаксимина и их применение
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
EP2558493A4 (en) ANTIBODIES FOR THE TREATMENT OF INFECTION AND DISEASE ASSOCIATED WITH DIFFICULT CLOSTRIDIUM
UA107827C2 (en) Antibody cd40
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
IN2012MN02591A (es)
MX366899B (es) Nuevos compuestos.
UA110103C2 (uk) Модифікований туберкульозний антиген
MX2014013149A (es) Anticuerpos anti-il-23p19.
IN2014DN03010A (es)
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
TN2013000265A1 (en) Anti-cd38 antibodies
UA111824C2 (uk) Лікарські форми рифаксиміну і їх застосування
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
FG Grant or registration